文献速递妇科

在晚期卵巢癌小鼠模型中,添加Fc-IgG可诱导受体聚集并增强凝血酶敏感蛋白-1 I型重复序列(3TSR)的体外疗效和体内抗肿瘤特性

Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-11-16

本研究在晚期上皮性卵巢癌小鼠模型中比较新型Fc融合构建体Fc3TSR与天然3TSR的体外和体内抗肿瘤效果。Fc3TSR较天然3TSR显著降低卵巢癌细胞和内皮细胞活力并增强CD36受体聚集,在体内诱导更强的血管正常化和疾病消退。

要点

  • Fc3TSR较天然3TSR显著降低上皮性卵巢癌细胞和内皮细胞的活力与增殖潜力。
  • Fc3TSR增强CD36受体聚集并伴随下游信号增强及更强的体外和体内细胞反应。
  • 在晚期卵巢癌原位同系小鼠模型中,Fc3TSR较天然3TSR诱导更强的血管正常化和疾病消退。

核心结论

  • Fc3TSR较3TSR尺寸更大、在循环中稳定并增强受体激活,促进其作为转移性晚期卵巢癌治疗的转化潜力。

研究设计与样本

  • 体外采用增殖和凋亡实验评估Fc3TSR与天然3TSR的疗效差异,并检测CD36受体聚集。
  • 体内采用晚期上皮性卵巢癌原位同系小鼠模型比较两种化合物对肿瘤血管形态的影响。

主要发现

  • Fc3TSR较天然3TSR显著降低上皮性卵巢癌细胞和内皮细胞的活力与增殖潜力。
  • 高分辨率成像与图像相关光谱显示Fc3TSR处理细胞中CD36受体聚集增强。
  • CD36受体聚集增强伴随下游信号增强及更强的体外和体内细胞反应。
  • 在晚期卵巢癌原位同系小鼠模型中,Fc3TSR较天然3TSR诱导更强的血管正常化和疾病消退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tumor vasculature is structurally abnormal, with anatomical deformities, reduced pericyte coverage and low tissue perfusion. As a result of this vascular dysfunction, tumors are often hypoxic, which is associated with an aggressive tumor phenotype, and reduced delivery of therapeutic compounds to the tumor. We have previously shown that a peptide containing the thrombospondin-1 type I repeats (3TSR) specifically targets tumor vessels and induces vascular normalization in a mouse model of epithelial ovarian cancer (EOC). However, due to its small size, 3TSR is rapidly cleared from circulation. We now introduce a novel construct with the 3TSR peptide fused to the C-terminus of each of the two heavy chains of the Fc region of human IgG1 (Fc3TSR). We hypothesize that Fc3TSR will have greater anti-tumor activity in vitro and in vivo compared to the native compound. METHODS: Fc3TSR was evaluated in vitro using proliferation and apoptosis assays to investigate differences in efficacy compared to native 3TSR. In light of the multivalency of Fc3TSR, we also investigate whether it induces greater clustering of its functional receptor, CD36. We also compare the compounds in vivo using an orthotopic, syngeneic mouse model of advanced stage EOC. The impact of the two compounds on changes to tumor vasculature morphology was also investigated. RESULTS: Fc3TSR significantly decreased the viability and proliferative potential of EOC cells and endothelial cells in vitro compared to native 3TSR. High-resolution imaging followed by image correlation spectroscopy demonstrated enhanced clustering of the CD36 receptor in cells treated with Fc3TSR. This was associated with enhanced downstream signaling and greater in vitro and in vivo cellular responses. Fc3TSR induced greater vascular normalization and disease regression compared to native 3TSR in an orthotopic, syngeneic mouse model of advanced stage ovarian cancer. CONCLUSION: The development of Fc3TSR which is greater in size, stable in circulation and enhances receptor activation compared to 3TSR, facilitates its translational potential as a therapy in the treatment of metastatic advanced stage ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matuszewska K, Ten Kortenaar S, Pereira M, et al. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer. Gynecol Oncol. 2021. PMID: 34799137. doi:10.1016/j.ygyno.2021.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。